G1 Therapeuticsincis A Biopharmaceutical Company Based In Research Triangle Parknorth Carolinafounded In 2008It Focuses On Developing Small Molecule Therapies For Cancer Treatmentthe Company Aims To Improve Patient Outcomes By Targeting Cellular Pathways Involved In Cancer Progressiong1 Therapeutics Became A Subsidiary Of Pharmacosmos A S In September 2024 The Company S Flagship Productcoselatrilaciclib Is An Fda Approved Drug That Protects Bone Marrow From Chemotherapy Damageit Is Administered Intravenously Before Chemotherapy To Enhance Patient Safetyg1 Therapeutics Also Has A Pipeline That Includes Lerocicliba Cdk4 6 Inhibitorand Other Investigational Compounds Aimed At Cancer Treatmentthe Company Collaborates With Organizations Like Genecentric Therapeutics And Astrazeneca To Advance Its Research And Clinical Trials
